107 results about "Peripheral neuropathy" patented technology

The treatment system includes a limb sleeve containing a heating subsystem, a pressure subsystem, and a vibration subsystem. The heating subsystem provides controlled cyclic heating to the limb, leading to dilation of the microvasculature and improved blood flow to nerve receptors. The pressure subsystem provides progressively staged, cyclic pressure to the limb, thereby improving blood circulation to the limb, reducing edema buildup, and flushing waste out the lymphatic system. The vibration subsystem provides controlled vibrotactile sensation to the limb to promote neuronal stimulation and decrease pain sensation. The treatment system allows for a multi-faceted approach in disease stabilization and assistive, personalized treatment for peripheral neuropathy.

There is provided a transvenous cryoneurolysis system and method for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. The system performs a variety of freeze-thaw cycles via the target vein to induce a desired axial cryolesion along a target nerve. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The present disclosure relates to compositions for increasing acetylated alpha-tubulin levels in peripheral neuronal cells. The present disclosure also relates to the use of tubulin deacetylase inhibitors, or activators of tubulin acetylation for increasing acetylated tubulin levels in the cells. The present disclosure also relates to methods for assessing risk of developing peripheral neuropathy by assessing the levels of acetylated alpha-tubulin. The present disclosure further relates to methods for treating a subject suffering from a peripheral neuropathy using the compositions described herein.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The invention discloses a traditional Chinese medicine combination effective part capable of improving diabetic peripheral neuropathy. The traditional Chinese medicine combination effective part is prepared from a volatile oil effective part, a water-soluble effective part and an alcohol-soluble effective part, the effective part of the volatile oil comprises alpha-ocimene, alpha-santalene, bisabolol, beta-bisabolol and nerolidol; the water-soluble effective part comprises salvianolic acid A, salvianolic acid B and tanshinol; the alcohol-soluble effective part is prepared from Z-ligustilide, alpha-masticinic acid, beta-masticinic acid, tanshinone IIA, and 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone, and the alcohol-soluble effective part is prepared from the following raw materials in parts by weight: 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone. The traditional Chinese medicine composition effective part provided by the invention can regulate blood sugar, improve the conduction speed of sciatic nerves, repair damaged tissues, inhibit oxidative stress reaction, resist inflammation and relieve pain, so that the diabetic peripheral neuropathy is improved, the curative effect is reliable, the safety is good, the adverse reaction is low, and the traditional Chinese medicine composition effective part can be used for preparing a medicinal preparation for improving the diabetic peripheral neuropathy.

The invention provides a traditional Chinese medicine preparation for treating peripheral neuropathy caused by chemotherapy, the traditional Chinese medicine preparation comprises an external preparation and an internal preparation, and discloses a preparation method and application of the traditional Chinese medicine preparation. The core pathogenesis of qi and blood stasis and yang deficiency and cold coagulation of the peripheral neuropathy caused by chemotherapy and the characteristic treatment method of tonifying qi and activating blood and warming yang and dredging collaterals are innovatively provided; the composition is rigorous and rigorous, and is clinically safe and effective.

The invention discloses an application of fenoterol hydrobromide and pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic peripheral neuropathy. The fenoterol hydrobromide and the pharmaceutically acceptable salt thereof have obvious effects of promoting growth of peripheral sensory neurite and protecting myelin sheath injury, and can improve symptoms of slow nerve conduction speed and sensory deficiency induced by diabetes mellitus.

The invention discloses a marker combination, a kit thereof and application of the marker combination to prediction of diabetic peripheral neuropathy, the marker combination comprises human angiotensin (ANG), human vascular endothelial cell adhesion molecule 1 (VCAM1) and human mannan binding lectin serine peptide 1 (MASP1), TMT quantitative proteomics and PRM targeted proteomics are adopted, and the marker combination is used for detecting diabetic peripheral neuropathy. A technology combination strategy of an ELISA experiment is adopted, and key differential expression proteins such as MASP1, VCAM1 and ANG in serum exosomes of patients with diabetic peripheral neuropathy are systematically screened and verified. By establishing a multi-model machine learning diagnosis system based on logistic regression, a support vector machine and a naive Bayes algorithm, simple and rapid identification of diabetic peripheral neuropathy patients is realized, and a new experimental basis is provided for clarification of a molecular regulation network of diabetic peripheral neuropathy; more importantly, a rapid screening tool with clinical application potential is developed.

The invention belongs to the technical field of medical apparatus and instruments, and discloses a household traditional Chinese medicine directional drug permeation device applied to chemotherapy-related peripheral neuropathy, the household traditional Chinese medicine directional drug permeation device comprises an adjustable electrode plate and an elastic bandage, the adjustable electrode plate comprises a main electrode plate and a branch electrode plate detachably mounted at any side position of the main electrode plate; the whole main electrode plate is of an E-shaped structure; square medicine cores are respectively arranged in the three-finger section of the main electrode plate and the rectangular grooves in the bottoms of the branch electrode plates; and elastic bandages cover the front and rear ends of the tops of the main electrode plate and the branch electrode plates. Through improvement and innovation of the shape of the electrode slice, the electrode slice is designed to be of an integrated structure according to the position relation of the eight-wind-eight-evil acupuncture points, the electrode slice is applied to drug penetration treatment of the eight-wind-eight-evil acupuncture points at the tail ends of the four limbs, a personalized treatment scheme can be provided according to the specific conditions of a patient, the treatment accuracy and effectiveness are enhanced, and the treatment cost is reduced. And a new normal form for treating the chemotherapy-related peripheral neuropathy is created.

The invention discloses a traditional Chinese medicine composition for treating diabetic peripheral neuropathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 10-20 parts of angelica sinensis, 8-15 parts of cassia twig, 8-15 parts of red paeony root, 15-30 parts of caulis spatholobi, 5-10 parts of tetrapanax papyriferus, 3-6 parts of scorpio and 1-3 parts of centipede.

The application discloses application of arctigenin derivative or a pharmaceutically acceptable salt thereof in preparation of a medicament for treating peripheral neuropathy in diabetes. The application shows through a large number of experiments that the arctigenin derivative and the pharmaceutically acceptable salt thereof can obviously improve nerve conduction velocity and sensory loss symptoms of diabetic mice, thereby achieving the effect of treating peripheral neuropathy.

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention provides a pharmaceutical composition for treating an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition comprising an alkalizing agent. By administering this pharmaceutical composition, it is possible to treat an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, in particular, a chemotherapeutic agent for cancer. The present invention also provides an anticancer pharmaceutical composition that contains an alkalizing agent and a chemotherapeutic agent for cancer and that is designed to suppress an acute-phase peripheral neuropathy induced by the chemotherapeutic agent or to suppress worsening of symptoms caused by the peripheral neuropathy. By administering this pharmaceutical composition, it is possible to provide a cancer treatment in which an acute-phase peripheral neuropathy or worsening of symptoms caused by the peripheral neuropathy is suppressed.

The present invention relates to a multilayer pharmaceutical or nutraceutical solid dosage form comprising at least one pyrimidine derivative, purine derivative or any salt or solvate thereof and least one B-group vitamin. It also provides three methods for producing said multilayer pharmaceutical or nutraceutical solid dosage forms. Furthermore, the present invention is also related to therapeutic uses of said multilayer pharmaceutical or nutraceutical solid dosage forms, particularly for the treatment and / or prevention of peripheral neuropathy.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

A method of treating or preventing peripheral neuropathies includes administering a therapeutically effective amount of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof to a patient who needs treatmentwherein, carbon marked with * is asymmetric carbon; and A represents a group represented by general formulae (IIa), (IIb) or (IIc):wherein R1 represents a methyl group or an ethyl group optionally substituted with a halogen atom, R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, each R3 independently represents a methyl group or an ethyl group, and n represents 1 or 2.

The invention provides application of ursodesoxycholic acid in preparation of a medicine for treating peripheral neuropathy. The ursodesoxycholic acid provided by the invention can promote the recovery of sciatic nerve function indexes after the sciatic nerve of a mouse is cut off, and improve the electroneurographic signal conduction function of an injured part; meanwhile, the UDCA can also relieve oxaliplatin-induced ischiadic nerve signal transduction disorder of mice and related crymodynia sensitive symptoms. In addition, the invention further reveals that the relieving effect of the UDCA on the peripheral neuropathy does not depend on promoting Schwann cell migration. According to the discovery, the application value of the UDCA in treating peripheral neuropathy caused by multiple factors is expanded, and a new strategy is provided for clinical treatment of the UDCA.

A composition for treating peripheral neuropathy in a subject in need thereof. The composition comprises an effective amount of an agent selected from the group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, muscarinic receptor antagonists, and combinations thereof, and a pharmaceutically acceptable carrier and / or excipient. The composition is used for treating peripheral neuropathy. Examples of the peripheral neuropathy are systemic disease-induced peripheral neuropathy, metabolic disease-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, compression-induced peripheral neuropathy, dichloroacetate-contact-induced peripheral neuropathy, immune-mediated peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy and chemotherapy-induced peripheral neuropathy. And infection-induced peripheral neuropathy and gene-obtained peripheral neuropathy.

The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and / or using the antibodies and / or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition, a preparation method and application of the traditional Chinese medicine composition to preparation of medicine for preventing or treating diabetic foot. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from leech, caulis spatholobi, lumbricus, radix paeoniae rubra, garden balsam stem, radix cyathulae, cassia twig, frankincense, myrrh, radix aconiti lateralis praeparata, angelica sinensis, rheum officinale, coptis chinensis and astragalus membranaceus. All the medicines are combined to play roles in promoting blood circulation and enriching blood, dredging channels and collaterals, improving nerve and blood vessel functions of lower limbs and promoting growth of local granulation tissues, so that the traditional Chinese medicine composition can be used for preventing or treating diabetic foot or complications thereof, and the complications comprise diabetic peripheral vasculopathy or diabetic peripheral neuropathy.

To provide a method for ameliorating adverse event peripheral neuropathies in a subject undergoing treatment with an anti- CD30 antibody-drug conjugate and optionally also receiving concomitant chemotherapies.SOLUTION: 1. Provided is a method of treating a subject who has exhibited peripheral neuropathy of Grade 2 or greater after initiating treatment with an anti- 2mg antibody-drug conjugate therapy at a dose of CD30 / kg or greater, comprising administering the anti- 9mg antibody-drug conjugate therapy at a dose of 0. CD30 / kg.SELECTED DRAWING: None

The application relates to the technical field of compound medicines, and discloses application of a compound external-use patch for preventing and treating diabetic peripheral neuropathy, wherein the compound external-use patch comprises a gel base and dry extract and volatile oil doped into the gel base, the dry extract and the volatile oil are derived from a compound, and the compound is composed of 10-20 parts of cinnamon, 8-12 parts of asarum, 8-12 parts of evodia, 8-12 parts of chuanxiong and 0.2-0.8 parts of borneol in terms of weight parts. The compound external-use patch of the application is locally pasted on acupoints or joints of DPN rats, can reduce the blood sugar level of diabetic peripheral neuropathy rats, increase the insulin level, improve insulin resistance, prolong the latent period of hot stimulation foot withdrawal, increase the nerve conduction velocity, maintain the normal morphology and function of nerve cells, and therefore can prevent and inhibit the generation and deterioration of diabetic peripheral neuropathy; and the compound external-use patch improves the safety and convenience of patients in taking medicine compared with oral medicine.

The application discloses application of a glucose transporter 1 inhibitor in preparation of a drug for treating diabetic neuropathy. The application verifies that the glucose transporter 1 inhibitor BAY-876 can be used as a drug for treating diabetic peripheral neuropathy and can be combined with mecobalamin to be used as a drug for treating diabetic peripheral neuropathy through pharmacodynamics experiments.

Provided herein is use of a polypeptide as neuroprotective agent. In particular, provided herein is a method for preventing and / or treating peripheral neuropathy or nerve injury associated with peripheral neuropathy in a subject in need thereof, comprising administering to the subject an effective amount of any one of the polypeptides provided herein.

Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.

The invention provides a traditional Chinese medicine composition for treating diabetic peripheral neuropathy. The traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by weight: 12 to 18 parts of herba dendrobii, 20 to 30 parts of radix astragali seu hedysari, 8 to 12 parts of fructus schizandrae, 10 to 15 parts of rhizoma anemarrhenae, 12 to 18 parts of radix puerariae, 15 to 25 parts of radix salviae miltiorrhizae, 8 to 12 parts of rhizoma coptidis, 9 to 15 parts of lumbricus, 15 to 30 parts of caulis spatholobi, 9 to 15 parts of rhizoma chuanxiong, 3 to 8 parts of centipede and 3 to 6 parts of radix aconiti carmichaeli. The traditional Chinese medicine composition has the effects of metabolic regulation, analgesia, nerve protection, anti-inflammation, immune regulation, autophagy regulation and nerve repair in treatment of diabetic peripheral neuropathy; the formula takes'qi tonifying, yin nourishing, root curing, blood circulation promoting, collateral dredging, stasis removing and symptom curing 'as the core, accords with the pathogenesis characteristics of DPN'deficiency of both qi and yin as the root and obstruction of collaterals by phlegm and blood stasis as the symptom', and realizes comprehensive treatment of DNP through multi-target regulation of glycolipid metabolism and inhibition of neuroinflammation and pathological autophagy.

The invention discloses a method for researching the action mechanism of saikoside D on paclitaxel-induced peripheral neuropathy, and relates to the technical field of disease mechanism research and drug development. Comprising the following steps: performing continuous administration through intraperitoneal injection of paclitaxel, and establishing a paclitaxel-induced peripheral neuropathy animal model; a von Frey cellosilk experiment and a cold and hot plate experiment are adopted for behavioral detection, and mechanical pain threshold and cold and hot pain sense changes are evaluated; the morphological structure change of the sciatic nerve myelin sheath is observed through Luxol Fast Blue staining; and the expression level of the myelin sheath basic protein in the sciatic nerve is detected by using immunofluorescence staining and Western blotting technologies. According to the invention, a closed-loop research system is formed from animal model construction to molecular mechanism verification; based on behavioral detection, histological analysis and multiple dimensions of a molecular biological technology, the data reliability is ensured, and the curative effect of saikoside D can be comprehensively evaluated.